Anti-SARS-CoV-2 Spike RBD antibody [CV30] (ab277513)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Human monoclonal [CV30] to SARS-CoV-2 Spike RBD
- Suitable for: Indirect ELISA
Overview
-
Product name
Anti-SARS-CoV-2 Spike RBD antibody [CV30]
See all SARS-CoV-2 Spike RBD primary antibodies -
Description
Human monoclonal [CV30] to SARS-CoV-2 Spike RBD -
Host species
Human -
Tested applications
Suitable for: Indirect ELISAmore details -
Immunogen
Tissue, cells or virus. This information is proprietary to Abcam and/or its suppliers.
-
General notes
CV30 cross-reacts with both SARS-CoV-2 Spike RBD and Ectodomain. CV30 demonstrates significant neutralising ability in in-direct ELISA, measuring competitive binding of CV30 to SARS-CoV-2 Spike RBD in the presence of human ACE2.
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.02% Proclin 300
Constituent: 99% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
CV30 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Images
-
Indirect ELISA showing ab277513 (CV30) binding to purified His-tagged SARS-CoV2-RBD. Plates were coated with 100ng/well purified protein and binding of ab277513 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
-
Indirect ELISA showing ab277513 (CV30) binding to ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)). Plates were coated with 100ng/well ab272105 and binding of ab277513 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
-
Indirect competition ELISA showing competitive binding of ab277513 (CV30) to purified Fc-tagged SARS-CoV2-RBD in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well SARS-CoV2-RBD and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
-
Indirect competition ELISA showing competitive binding of ab277513 (CV30) to ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)) in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well ab272105 and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
-